{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:06:31Z","timestamp":1790676391317,"version":"4.1.0"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>With the Food and Drug Administration and other worldwide regulatory authorities\u2019 approval of ipilimumab (Yervoy), sipuleucel-T (Provenge), nivolumab (Opdivo), and pembrolizumab (Keytruda), oncologic therapy has now moved into noncancer cell targets within the immune system. For many nonimmunologists, understanding how these vastly different therapies work to improve survival, like no other therapies have in the past, is a challenge. The present report reviews the normal function of the immune system, how cancers escape the normal immune system, and how these new therapies improve immune system reactions against cancers.<\/jats:p>","DOI":"10.1634\/theoncologist.2015-0282","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T04:13:31Z","timestamp":1454386411000},"page":"233-243","source":"Crossref","is-referenced-by-count":86,"title":["How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances"],"prefix":"10.1093","volume":"21","author":[{"given":"Jonathan L.","family":"Messerschmidt","sequence":"first","affiliation":[{"name":"a Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA"},{"name":"b Lankenau Medical Center, Wynnewood, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C.","family":"Prendergast","sequence":"additional","affiliation":[{"name":"a Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA"},{"name":"b Lankenau Medical Center, Wynnewood, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald L.","family":"Messerschmidt","sequence":"additional","affiliation":[{"name":"a Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA"},{"name":"b Lankenau Medical Center, Wynnewood, Pennsylvania, USA"},{"name":"c Clinical Research Center, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"key":"2021122309524164600_B1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122309524164600_B2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122309524164600_B3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122309524164600_B4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122309524164600_B5","article-title":"FDA expands approved use of Opdivo in advanced lung cancer. Opdivo demonstrates survival benefit in squamous and non-squamous non-small cell lung cancer","volume-title":"N Engl J Med","author":"FDA News Release","year":"2015"},{"key":"2021122309524164600_B6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122309524164600_B7","volume-title":"Pembrolizumab","author":"FDA News Release"},{"key":"2021122309524164600_B8","volume-title":"FDA approves Keytruda for advanced non-small cell lung cancer. First drug approved in lung cancer for patients whose tumors express PD-L1","author":"FDA News Release"},{"issue":"suppl","key":"2021122309524164600_B9","doi-asserted-by":"crossref","first-page":"TPS8103a","DOI":"10.1200\/jco.2015.33.15_suppl.tps8103","article-title":"KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1)","volume":"33","author":"Brahmer","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122309524164600_B10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF02933937","article-title":"Beitr\u00e4ge zur Kenntniss der Anilinf\u00e4rbungen und ihrer Verwendung in der mikroskopischen Technik","volume":"13","author":"Ehrlich","year":"1877","journal-title":"Arch Mikroskopische Anat"},{"key":"2021122309524164600_B11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00000441-189305000-00001","article-title":"The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases","volume":"105","author":"Coley","year":"1893","journal-title":"Am J Med Sci"},{"key":"2021122309524164600_B12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0305-7372(96)90023-7","article-title":"Spontaneous regression of cancer","volume":"22","author":"Papac","year":"1996","journal-title":"Cancer Treat Rev"},{"key":"2021122309524164600_B13","first-page":"571","article-title":"Spontaneous regression of cancer: Possible mechanisms","volume":"12","author":"Papac","year":"1998","journal-title":"In Vivo"},{"key":"2021122309524164600_B14","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1073\/pnas.73.9.3278","article-title":"Cell surface antigens of human malignant melanoma: Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells","volume":"73","author":"Carey","year":"1976","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309524164600_B15","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1084\/jem.150.3.564","article-title":"Cell surface antigens of human renal cancer defined by autologous typing","volume":"150","author":"Ueda","year":"1979","journal-title":"J Exp Med"},{"key":"2021122309524164600_B16","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1073\/pnas.81.11.3511","article-title":"T-cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin 2-dependent T-cell cultures","volume":"81","author":"Knuth","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309524164600_B17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00000658-195609000-00007","article-title":"Spontaneous regression of cancer: Preliminary report","volume":"144","author":"Cole","year":"1956","journal-title":"Ann Surg"},{"key":"2021122309524164600_B18","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1172\/JCI116278","article-title":"Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma: Evidence for in situ T cell clonal expansion","volume":"91","author":"Ferradini","year":"1993","journal-title":"J Clin Invest"},{"key":"2021122309524164600_B19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/(SICI)1521-4141(199902)29:02<602::AID-IMMU602>3.0.CO;2-Y","article-title":"A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion","volume":"29","author":"Zorn","year":"1999","journal-title":"Eur J Immunol"},{"key":"2021122309524164600_B20","first-page":"529","volume-title":"Cellular and Humoral Aspects of the Hypersensitive States: A Symposium Held at the New York Academy of Medicine. New York Academy of Medicine: Symposia of the Section on Microbiology","author":"Thomas","year":"1959"},{"key":"2021122309524164600_B21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.1.5022.779","article-title":"Cancer: A biological approach. I. The processes of control","volume":"1","author":"Burnet","year":"1957","journal-title":"BMJ"},{"key":"2021122309524164600_B22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: From immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"2021122309524164600_B23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2021122309524164600_B24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/381616a0","article-title":"T-cell-receptor affinity and thymocyte positive selection","volume":"381","author":"Alam","year":"1996","journal-title":"Nature"},{"key":"2021122309524164600_B25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0092-8674(94)90169-4","article-title":"T cell receptor antagonist peptides induce positive selection","volume":"76","author":"Hogquist","year":"1994","journal-title":"Cell"},{"key":"2021122309524164600_B26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ni.2190","article-title":"How the TCR balances sensitivity and specificity for the recognition of self and pathogens","volume":"13","author":"Morris","year":"2012","journal-title":"Nat Immunol"},{"key":"2021122309524164600_B27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nri1780","article-title":"Microenvironmental niches in the bone marrow required for B-cell development","volume":"6","author":"Nagasawa","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"2021122309524164600_B28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1034\/j.1600-065X.2000.00607.x","article-title":"B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms","volume":"176","author":"Vos","year":"2000","journal-title":"Immunol Rev"},{"key":"2021122309524164600_B29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.smim.2007.12.002","article-title":"Plasma cell development: From B-cell subsets to long-term survival niches","volume":"20","author":"Fairfax","year":"2008","journal-title":"Semin Immunol"},{"key":"2021122309524164600_B30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nri1572","article-title":"Regulation of plasma-cell development","volume":"5","author":"Shapiro-Shelef","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"2021122309524164600_B31","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/eji.200324576","article-title":"Mini-review CD4 T cells are required for CD8 T cell memory generation","volume":"33","author":"Bourgeois","year":"2003","journal-title":"Eur J Immunol"},{"key":"2021122309524164600_B32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2010.02.008","article-title":"The synapse and cytolytic machinery of cytotoxic T cells","volume":"22","author":"Jenkins","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"2021122309524164600_B33","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1413","article-title":"Helping the CD8(+) T-cell response","volume":"4","author":"Bevan","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"2021122309524164600_B34","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nri2619","article-title":"The precursors of memory: Models and controversies","volume":"9","author":"Ahmed","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2021122309524164600_B35","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/nri1246","article-title":"Dendritic-cell control of pathogen-driven T-cell polarization","volume":"3","author":"Kapsenberg","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"2021122309524164600_B36","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"2021122309524164600_B37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ni0503-399","article-title":"Delivering the kiss of death","volume":"4","author":"Trambas","year":"2003","journal-title":"Nat Immunol"},{"key":"2021122309524164600_B38","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1084\/jem.192.5.755","article-title":"Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma","volume":"192","author":"Smyth","year":"2000","journal-title":"J Exp Med"},{"key":"2021122309524164600_B39","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1146\/annurev.iy.12.040194.003511","article-title":"The binding and lysis of target cells by cytotoxic lymphocytes: Molecular and cellular aspects","volume":"12","author":"Berke","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"2021122309524164600_B40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0167-5699(95)80069-7","article-title":"Fas and Fas ligand: LPR and GLD mutations","volume":"16","author":"Nagata","year":"1995","journal-title":"Immunol Today"},{"key":"2021122309524164600_B41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0092-8674(95)90365-8","article-title":"The CTL\u2019s kiss of death","volume":"81","author":"Berke","year":"1995","journal-title":"Cell"},{"key":"2021122309524164600_B42","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1038\/onc.2008.35","article-title":"Immune escape as a fundamental trait of cancer: Focus on IDO","volume":"27","author":"Prendergast","year":"2008","journal-title":"Oncogene"},{"key":"2021122309524164600_B43","volume-title":"On the Origin of Species by Means of Natural Selection, or the Preservation of Favoured Races in the Struggle for Life","author":"Darwin"},{"key":"2021122309524164600_B44","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrclinonc.2011.72","article-title":"Immunotherapy for the treatment of prostate cancer","volume":"8","author":"Di Lorenzo","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122309524164600_B45","volume-title":"(2011-03-25) FDA approves new treatment for a type of late-stage skin cancer (press release). U.S. Food and Drug Administration (FDA)","author":"Jefferson"},{"key":"2021122309524164600_B46","volume-title":"Drugs.com. Yervoy side effects"},{"key":"2021122309524164600_B47","volume-title":"Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. European Cancer Congress (ECCO) Amsterdam 2013, abstract 24"},{"key":"2021122309524164600_B48","volume-title":"Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)"},{"key":"2021122309524164600_B49","volume-title":"Phase I\/II Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer (MDX010-21)"},{"key":"2021122309524164600_B50","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"2021122309524164600_B51","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"key":"2021122309524164600_B52","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"2021122309524164600_B53","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-04-2671","article-title":"Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells","volume":"11","author":"Okamoto","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122309524164600_B54","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.molmed.2015.05.005","article-title":"Checkpoint blockade for cancer therapy: Revitalizing a suppressed immune system","volume":"21","author":"Pico de Coa\u00f1a","year":"2015","journal-title":"Trends Mol Med"},{"key":"2021122309524164600_B55","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2021122309524164600_B56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett"},{"key":"2021122309524164600_B57","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med"},{"key":"2021122309524164600_B58","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122309524164600_B59","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122309524164600_B60","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-04-0428","article-title":"B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression","volume":"10","author":"Konishi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122309524164600_B61","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122309524164600_B62","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309524164600_B63","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1593\/neo.05733","article-title":"The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors","volume":"8","author":"Ghebeh","year":"2006","journal-title":"Neoplasia"},{"key":"2021122309524164600_B64","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res"},{"key":"2021122309524164600_B65","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: From discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"2021122309524164600_B66","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity","volume":"9","author":"Curiel","year":"2003","journal-title":"Nat Med"},{"key":"2021122309524164600_B67","first-page":"6501","article-title":"B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma","volume":"63","author":"Strome","year":"2003","journal-title":"Cancer Res"},{"key":"2021122309524164600_B68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122309524164600_B69","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"2021122309524164600_B70","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y","article-title":"A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells","volume":"29","author":"Magistrelli","year":"1999","journal-title":"Eur J Immunol"},{"key":"2021122309524164600_B71","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ni846","article-title":"CTLA-4-Ig regulates tryptophan catabolism in vivo","volume":"3","author":"Grohmann","year":"2002","journal-title":"Nat Immunol"},{"key":"2021122309524164600_B72","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.4049\/jimmunol.172.7.4100","article-title":"Ligation of B7-1\/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells","volume":"172","author":"Munn","year":"2004","journal-title":"J Immunol"},{"key":"2021122309524164600_B73","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","article-title":"Prevention of allogeneic fetal rejection by tryptophan catabolism","volume":"281","author":"Munn","year":"1998","journal-title":"Science"},{"key":"2021122309524164600_B74","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-1-4419-0170-5_15","volume-title":"Targeted Cancer Immune Therapy","author":"Katz","year":"2009"},{"issue":"suppl","key":"2021122309524164600_B75","doi-asserted-by":"crossref","first-page":"3069a","DOI":"10.1200\/jco.2013.31.15_suppl.3069","article-title":"A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors","volume":"31","author":"Soliman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122309524164600_B76","doi-asserted-by":"crossref","first-page":"3026a","DOI":"10.1200\/jco.2013.31.15_suppl.3026","article-title":"A phase I study of Indoximod in combination with docetaxel in metastatic solid tumors","volume":"31","author":"Jackson","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309524164600_B77","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.4049\/jimmunol.1303012","article-title":"IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis","volume":"192","author":"Merlo","year":"2014","journal-title":"J Immunol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0282","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0282","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/2\/233\/41874813\/oncolo_21_2_233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/2\/233\/41874813\/oncolo_21_2_233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:14:37Z","timestamp":1640319277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/2\/233\/6401118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":77,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,1]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0282","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,2,1]]},"published":{"date-parts":[[2016,2,1]]}}}